Biotechnology News and Research

RSS

Moderna Therapeutics closes $40M in financing

Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development.

6 Dec 2012

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

RXi Pharmaceuticals Corporation, today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

5 Dec 2012

New method can generate stable human mesenchymal stem cells for bone engineering

Human mesenchymal stem cells (hMSCs) can develop into bone cells and are useful for tissue engineering and regeneration. However, when grown in the laboratory they quickly lose their ability to continue dividing and they die.

5 Dec 2012

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells.

5 Dec 2012

Study explores osteoporosis racial differences in women

About 30 million women in the U.S. have osteoporosis, with low bone mass and deteriorating bone structure that increases their risk for fractures. Racial differences in the rates of detection and management of osteoporosis were explored in a study of African American and white women published in Journal of Women's Health, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

5 Dec 2012

Baxter enters definitive agreement to acquire Gambro

Baxter International Inc. has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK (approximately $4.0 billion USD at current exchange rates).

From Baxter International Inc. 5 Dec 2012

New antibodies effective at preventing formation of toxic protein particles linked to Parkinson’s, AD

Antibodies developed by researchers at Rensselaer Polytechnic Institute are unusually effective at preventing the formation of toxic protein particles linked to Alzheimer's disease and Parkinson's disease, as well as Type 2 diabetes, according to a new study.

4 Dec 2012

New study on incidence of breast cancer in Italy

A new study on the incidence of breast cancer in Italy has been published in the International Journal of Experimental and Clinical Cancer Research.

1 Dec 2012

Rensselaer nano-photonics expert named American Association for the Advancement of Science fellow

Nano-photonics expert Shawn Yu-Lin, professor of physics at Rensselaer Polytechnic Institute and a member of the university's Future Chips Constellation and Smart Lighting Engineering Research Center, has been selected as a fellow of the American Association for the Advancement of Science (AAAS).

30 Nov 2012

Modified vitamin D receptor may reduce risk of osteoporosis

Osteoporosis, or reduced bone mineral density that can increase the risk of fractures, may affect as many as 30% of women and 12% of men worldwide. One risk factor for osteoporosis is vitamin D deficiency.

30 Nov 2012

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).

30 Nov 2012

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

A three-month-old Winnipeg girl has become the first patient in Canada to receive an experimental and potentially life-saving form of therapy to improve the function of her liver.

29 Nov 2012

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

Exelixis, Inc. today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for COMETRIQ (cabozantinib) for the proposed indication of treatment of progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).

29 Nov 2012

ArmaGen closes $17M Series A financing

ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics.

29 Nov 2012

Majority of parents with autistic child show interest in having genetic tests

The vast majority (80 percent) of parents with at least one child with Autism Spectrum Disorder (ASD) would pursue genetic testing if a test were available that could identify risk in a younger sibling, citing the desire for earlier identification of children at risk, earlier evaluation and intervention, closer monitoring and lessened anxiety.

29 Nov 2012

Bend Research, PATH and FhCMB develop new technology for thermostable vaccine production

Bend Research Inc., PATH, and Fraunhofer USA Center for Molecular Biotechnology (FhCMB) announce the development of a new technology for the production of thermostable vaccines. Utilizing novel formulation and spray-drying processing methods, the technology has enabled scientists at Bend Research, PATH, and FhCMB to develop a spray-dried influenza vaccine product that is stable at 50°C for over 2 months. The technology can also be applied to emerging influenza and other vaccines.

29 Nov 2012

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.

29 Nov 2012

Biotechnology News and Research

Moderna Therapeutics closes $40M in financing

RXi commences RXI-109 Phase 1 study for management of surgical scars and keloids

New method can generate stable human mesenchymal stem cells for bone engineering

Nanoparticle-based drug delivery attacks cancer cells without harming normal ones

Study explores osteoporosis racial differences in women

Baxter enters definitive agreement to acquire Gambro

New antibodies effective at preventing formation of toxic protein particles linked to Parkinson’s, AD

New study on incidence of breast cancer in Italy

Rensselaer nano-photonics expert named American Association for the Advancement of Science fellow

Modified vitamin D receptor may reduce risk of osteoporosis

Exelixis announces FDA approval of COMETRIQ for treatment of medullary thyroid cancer

Alberta Children's Hospital performs first liver cell transplant in Calgary, Canada

European Medicines Agency accepts Exelixis’ COMETRIQ MAA for review

ArmaGen closes $17M Series A financing

Majority of parents with autistic child show interest in having genetic tests

Bend Research, PATH and FhCMB develop new technology for thermostable vaccine production

Fertility treatment auto-injector: an interview with Lai Chiu Tang, Senior Industrial Designer at Cambridge Consultants

China's SFDA approves QIAGEN careHPV Test and instrument platform

Injecting Wnt7a protein could prevent Duchenne muscular dystrophy

Enrollment begins in Elan’s ELND005 Phase 2 trial for agitation/aggression associated with AD

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News